Compare HOVR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | BDSX |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | HOVR | BDSX |
|---|---|---|
| Price | $1.81 | $8.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 976.5K | 65.6K |
| Earning Date | 01-13-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | $55.08 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.35 | $3.44 |
| 52 Week High | $4.18 | $32.20 |
| Indicator | HOVR | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 57.34 |
| Support Level | $1.70 | $7.24 |
| Resistance Level | $1.69 | $8.69 |
| Average True Range (ATR) | 0.14 | 0.65 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 96.40 | 83.84 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.